PreF-Specific RSV Antibodies for Broad Neutralization

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments and vaccines for Respiratory Syncytial Virus (RSV) are limited, with no approved vaccines and existing monoclonal antibodies requiring multiple doses and causing hypersensitivity reactions, highlighting the need for highly specific, high-affinity antibodies that can neutralize both RSV subtypes and preferentially target the preF conformation of the F protein.

Innovation Solution

Development of a panel of RSV F-specific monoclonal antibodies from human memory B cells, which exhibit enhanced specificity and potency for the preF conformation, providing therapeutic and prophylactic candidates for treating and preventing RSV infection.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If existing monoclonal antibodies are used for RSV prophylaxis, then protective immunity is provided, but multiple doses are required and hypersensitivity reactions occur

Engineering Contradiction:

Improveprotective immunityVSAvoidmultiple doses required

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent applies parameter changes by developing antibodies with altered binding affinity parameters. The new antibodies exhibit significantly higher neutralization potency (up to 100-fold greater) against RSV, which changes the dosage parameter from multiple administrations to potentially single-dose efficacy, resolving the contradiction between providing protective immunity and reducing treatment complexity

Inventive Principle:

Principle #35Parameter changes

2Reliability

If existing monoclonal antibodies are used for RSV prophylaxis, then protective immunity is provided, but hypersensitivity reactions occur

Engineering Contradiction:

Improveprotective immunityVSAvoidhypersensitivity reactions

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the immunogenicity parameter by developing fully human antibodies through B cell sorting technology. This parameter change eliminates hypersensitivity reactions associated with non-human antibodies while maintaining protective immunity, as the human antibody sequences are immunologically compatible with human recipients

Inventive Principle:

Principle #35Parameter changes

3Quantity of substance

If high neutralization potency is achieved, then lower doses are required, but antibody development complexity increases

Engineering Contradiction:

Improveantibody doseVSAvoidantibody development process

Core Design Contradiction:

Quantity of substanceVSDevice complexity

Solution Approach 1:

The patent applies self-service by using in vivo affinity maturation where the human immune system naturally selects and optimizes high-affinity antibodies against RSV. The B cell sorting technology leverages the body's own immune memory to automatically generate high-potency antibodies, reducing the need for complex in vitro engineering while achieving 100-fold greater neutralization potency

Inventive Principle:

Principle #25Self-service

Solution Approach 2:

The patent changes the affinity parameter through natural immune processes. By sorting B cells that have undergone somatic hypermutation in vivo, the method obtains antibodies with optimized binding parameters, achieving high neutralization potency without requiring complex artificial affinity maturation procedures

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS20250388653A1Anti-respiratory syncytial virus antibodies, and methods of their generation and use

Publication Date: 2025.12.25 ADIMAB LLC

AI summary

Anti-RSV antibodies with neutralizing potency against RSV subtype A and RSV subtype B are provided, as well as methods for their identification, isolation, generation, and methods for their preparation and use are provided.